Guidelines on genetic evaluation and management of lynch syndrome: A consensus statement by the us multi-society task force on colorectal cancer

Diseases of the Colon and Rectum

Volumn 57, Issue 8, 2014, Pages 1025-1048

  Giardiello, Francis M ^a   Allen, John I ^b   Axilbund, Jennifer E ^a   Boland, C Richard ^c   Burke, Carol A ^d   Burt, Randall W ^e   Church, James M ^d   Dominitz, Jason A ^f,g   Johnson, David A ^h   Kaltenbach, Tonya ⁱ   Levin, Theodore R ^j   Lieberman, David A ^k   Robertson, Douglas J ^l,m   Syngal, Sapna ^n,o,p   Rex, Douglas K ^q  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

^j KAISER PERMANENTE MEDICAL CENTER   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l VA MEDICAL CENTER   (United States)

^m DARTMOUTH MEDICAL SCHOOL   (United States)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o DANA FARBER CANCER INSTITUTE   (United States)

^p HARVARD MEDICAL SCHOOL   (United States)

^q INDIANA UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MISMATCH REPAIR PROTEIN;

ARTICLE; CANCER PATIENT; CHEMOPROPHYLAXIS; COLON RESECTION; CONSENSUS; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM CANCER; EVIDENCE BASED PRACTICE; GENETIC COUNSELING; GENETIC SCREENING; GERMLINE MUTATION; HEALTH CARE PERSONNEL; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MICROSATELLITE INSTABILITY; MULTIMODALITY CANCER THERAPY; OVARIECTOMY; OVARY CANCER; PANCREAS CANCER; PATIENT CARE; PEDIGREE; PRACTICE GUIDELINE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SMALL INTESTINE CANCER; STOMACH CANCER; URINARY TRACT CANCER;

FEMALE; HUMANS; MALE; NEOPLASMS; NEOPLASMS, MULTIPLE PRIMARY;

EID: 84904905330     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.000000000000000     Document Type: Article

References (164)

1. R. Siegel, D. Naishadham, A. Jemal, Cancer statistics, 2013, CA Cancer J Clin 63 (2013) 11-30.
2. E.A. Platz, W.C. Willett, G.A. Colditz, et al., Proportion of colorectal cancer risk that might be preventable in a cohort of middle-aged US men, Cancer Causes Control 11 (2000) 579-588. (Pubitemid 30636357)
3. P. Lichtenstein, N.V. Holm, P.K. Verkasalo, Environmental and heritable factors in the causation of cancer-analysis of cohorts of twins from Sweden, Denmark, and Finland, N Engl J Med 343 (2000) 78-85. (Pubitemid 30451850)
4. L.A. Aaltonen, R. Salovaara, P. Kristo, et al., Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening of the disease, N Engl J Med 338 (1998) 1481-1487. (Pubitemid 28226275)
5. R.A. Barnetson, A. Tenesa, S.M. Farrington, et al., Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer, N Engl J Med 354 (2006) 2751-2763. (Pubitemid 43974193)
6. H. Hampel, W.L. Frankel, E. Martin, et al., Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer), N Engl J Med 352 (2005) 1851-1860.
7. V. Pinol, A. Castells, M. Andreu, et al., Gastrointestinal Oncology Group of the Spanish Gastroenterology Association, accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer, JAMA 293 (2005) 1986-1994. (Pubitemid 40570892)
8. R. Salovaara, A. Loukkola, P. Kristo, et al., Population-based molecular detection of hereditary nonpolyposis colorectal cancer, J Clin Oncol 182 (2000) 193-200.
9. H.T. Lynch, M.W. Shaw, C.W. Magnuson, et al., Hereditary factors in cancer. Study of two large midwestern kindreds, Arch Intern Med 117 (1966) 206-212.
10. R. Fishel, M.K. Lescoe, M.R.S. Rao, et al., The human mutator gene homolog hMSH2 and its association with hereditary nonpolyposis colon cancer, Cell 75 (1993) 1027-1038 (Pubitemid 24014559)
11. F.S. Leach, N. Nicolaides, N. Papadopoulos, et al., Mutations of a MutS homolog in hereditary non-polyposis colorectal cancer, Cell 75 (1993) 1215-1255.
12. N. Papadopoulos, N.C. Nicolaides, Y.-F. Wei, et al., Mutation of a mutL homolog in hereditary colon cancer, Science 263 (1994) 1625-1629. (Pubitemid 24128369)
13. C.E. Bronner, S.M. Baker, P.T. Morrison, et al., Mutations in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary nonpolyposis colon cancer, Nature 368 (1994) 258-261.
14. National Cancer Institute. Levels of evidence for cancer genetic studies (PDQ). 2012. Available at: http://www.cancer.gov/cancertopics/pdq/levels- evidence-genetics. Accessed November 1, 2013.
15. G.H. Guyatt, A.D. Oxman, G.E. Vist, et al., GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ 336 (2008) 924-926. (Pubitemid 351632017)
16. C.R. Boland, F.J. Troncale, Familial colonic cancer without antecedent polyposis, Ann Intern Med 100 (1984) 700-701. (Pubitemid 14143948)
17. V. Bonadona, B. Bonaïti, S. Olschwang, et al., Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome, JAMA 30 (2011) 2304-2310.
18. M.G. Dunlap, S.M. Farrington, A.D. Carothers, et al., Cancer risk associated with germline DNA mismatch repair gene mutations, Hum Mol Genet 6 (1997) 105-110. (Pubitemid 27033972)
19. F. Quehenberger, H.F. Vasen, H.C. van Houwelingen, Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment, J Med Genet 42 (2005) 491-496. (Pubitemid 40847237)
20. M.A. Jenkins, L. Baglietto, J.G. Dowty, et al., Cancer risks for mismatch repair gene mutation carriers: a population-based early onset care-family study, Clin Gastroenterol Hepatol 4 (2006) 489-498.
21. F. Alarcon, C. Lasset, J. Carayol, et al., Estimating cancer risk in HNPCC by the BRL method, Eur J Hum Genet 15 (2007) 831-836. (Pubitemid 47109041)
22. L. Baglietto, N.M. Lindor, J.G. Dowty, et al., Risks of Lynch syndrome cancers for MSH6 mutation carriers, J Natl Cancer Inst 102 (2010) 193-201.
23. Y.H. Choi, M. Cotterchio, G. McKeown-Eyssen, et al., Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario, Hered Cancer Clin Pract 7 (2009) 14.
24. Y.M. Hendriks, A. Wagner, H. Morreau, et al., Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance, Gastroenterology 127 (2004) 17-25. (Pubitemid 38962270)
25. L. Senter, M. Clendenning, K. Sotamaa, et al., The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations, Gastroenterology 135 (2008) 419-428.
26. H. Hampel, W.L. Frankel, E. Martin, et al., Feasibility of screening for Lynch syndrome among patients with colorectal cancer, J Clin Oncol 26 (2008) 5783-5788.
27. H.R. Vasen, Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer (HNPCC)], Fam Cancer 4 (2005) 219-225.
28. H. Hampel, J.A. Stephens, E. Pukkala, et al., Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset, Gastroenterology 129 (2005) 415-421. (Pubitemid 41096629)
29. Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/. Accessed November 1, 2013.
30. H.T. Lynch, T.C. Smyrk, P. Watson, et al., Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an update review, Gastroenterology 104 (1993) 1535-1549. (Pubitemid 23235432)
31. W.H. de Vos tot Nederveen Cappel, F.M. Nagengast, G. Griffioen, et al., Survellance for hereditary nonpolyposis colorectal cancer: a long-term study of 114 families, Dis Colon Rectum 45 (2002) 1588-1594. (Pubitemid 35471007)
32. S. Parry, A.K. Win, B. Parry, et al., Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery, Gut 60 (2011) 950-957.
33. A.K. Win, S. Parry, B. Parry, et al., Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers, Ann Surg Oncol 20 (2013) 1829-1836.
34. D.L. Edelstein, J.E. Axilbund, M. Baxter, et al., Rapid development of colorectal neoplasia in patients with Lynch syndrome, Clin Gastroenterol Hepatol 9 (2011) 340-343.
35. J.R. Jass, S.M. Stewart, J. Stewart, et al., Hereditary nonpolyposis colorectal cancer-morphologies, genes and mutations, Mut Res 310 (1994) 125-133. (Pubitemid 24302727)
36. M.A. Jenkins, S. Hayashi, A.M. O'Shea, et al., Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population based study, Gastroenterology 133 (2007) 48-56. (Pubitemid 47039240)
37. P. Peltomaki, G.J.A. Offerhaus, H.F.A. Vasen, Lynch syndrome, in: F.T. Bosman, F. Carneiro, R.H. Hruban (Eds.), WHO classification of tumors of the digestive system, Stylus Publishing, Sterling, VA, 2010, pp. 152-155.
38. R. Gryfe, H. Kim, E.T.K. Hsieh, et al., Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer, N Engl J Med 342 (2000) 69-77. (Pubitemid 30036597)
39. M. Aarnio, R. Sankila, E. Pukkala, et al., Cancer risk in mutation carriers of DNA-mismatch-repair genes, Int J Cancer 81 (1999) 214-218. (Pubitemid 29144749)
40. H.R. Vasen, A. Stormorken, F.H. Menko, et al., MSH2 mutation carriers are a higher risk for cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families, J Clin Oncol 19 (2001) 4074-4080. (Pubitemid 32976695)
41. G. Ponti, L. Losi, M. Pedroni, et al., Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or kertoacanthomas, J Invest Dermatol 126 (2006) 2302-2307. (Pubitemid 44413178)
42. C.D. South, H. Hampel, I. Comeras, et al., The frequency of Muir-Torre syndrome among Lynch syndrome families, J Natl Cancer Inst 100 (2008) 277-281. (Pubitemid 351480531)
43. P. Watson, R. Burzow, H.T. Lynch, et al., The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer, Gynecol Oncol 82 (2001) 223-228. (Pubitemid 32730595)
44. E. Barrow, L. Robinson, W. Alduaij, et al., Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations, Clin Genet 75 (2009) 141-149.
45. M. Aarnio, R. Salovaara, L.A. Aaltonen, et al., Features of gastric cancer in hereditary non-polyposis colorectal cancer, Int J Cancer 74 (1997) 551-555. (Pubitemid 27486515)
46. P. Watson, H.F. Vasen, J.P. Mecklin, et al., The risk of extra-colonic, extra-endometrial cancer in Lynch syndrome, Int J Cancer 123 (2008) 444-449. (Pubitemid 351842032)
47. L.G. Capelle, N.C. Van Grieken, H.F. Lingsma, et al., Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands, Gastroenterology 138 (2010) 487-492.
48. C. Engel, M. Loeffler, V. Steinke, et al., Risks of less common cancers in proven mutation carriers with lynch syndrome, J Clin Oncol 30 (2012) 4409-4415.
49. R.S. van der Post, L.A. Kiemeney, M.J. Ligtenberg, et al., Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers, J Med Genet 47 (2010) 464-470.
50. F. Kastrinos, E.M. Stoffel, J. Balmana, et al., Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1914 individuals undergoing clinical genetic testing in the United States, Cancer Epidemiol Biomarkers Prev 17 (2008) 2044-2051.
51. A.K. Win, J.P. Young, N.M. Lindor, Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study, J Clin Oncol 30 (2012) 958-964.
52. Axilbund JE, Klein AP, Bacon JA, et al. Risk of pancreatic cancer in hereditary nonpolyposis colorectal cancer. Insight Meeting, Dusseldorf, Germany, June 24-27, 2009.
53. E.M. Grindedal, P. Moller, R. Eeles, et al., Germ-line mutations in mismatch repair genes associated with prostate cancer, Cancer Epidemiol Biomarkers Prev 18 (2009) 2460-2467.
54. F. Kastrinos, B. Mukherjee, N. Tayob, et al., Risk of pancreatic cancer in families with Lynch syndrome, JAMA 302, 2009. 1790-175.
55. A. Muller, T.B. Edmonston, D.A. Corao, et al., Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer, Cancer Res 62 (2002) 1014-1019. (Pubitemid 34160280)
56. H.F. Vasen, H. Morreau, J.W. Nortier, Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer?, Am J Hum Genet 68 (2001) 1533-1535. (Pubitemid 32510631)
57. M.D. Walsh, D.D. Buchanan, M.C. Cummings, et al., Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry, Clin Cancer Res 16 (2010) 2214-2224.
58. N. Buerki, L. Gautier, M. Kovac, et al., Evidence for breast cancer as an integral part of Lynch syndrome, Genes Chromosomes Cancer 51 (2012) 83-91.
59. V.M. Raymond, B. Mukherjee, F. Wang, et al., Elevated risk of prostate cancer among men with Lynch syndrome, J Clin Oncol 31 (2013) 1713-1718.
60. S.B. Gruber, Cancer genetics: lesions from colorectal cancer, in: D.P. Kelsen, J.M. Daly, S.E. Kern (Eds.), Gastrointestinal oncology: principles and practice, Lippincott William and Wilkins, Philadelphia, PA, 2002, pp. 1635-1639.
61. J. Teruya-Feldstein, J. Greene, L. Cohen, et al., Analysis of mismatch repair defects in the familial occurrence of lymphoma and colorectal cancer, Leuk Lymphoma 43 (2002) 1619-1626. (Pubitemid 34823483)
62. M. Nilbert, C. Therkildsen, A. Nissen, et al., Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphologic spectrum, Fam Cancer 8 (2009) 209-213.
63. J.D. Trimbath, G.M. Petersen, S.H. Erdman, et al., Cafe-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC?, Fam Cancer 1 (2001) 101-105. (Pubitemid 35221523)
64. C.A. Durno, S. Holter, P.M. Sherman, et al., The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations, Am J Gastroenterol 105 (2010) 2449-2456.
65. H.F.A. Vasen, J.P. Mecklin, P. Meera Khan, et al., The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer, Dis Colon Rect 34 (1991) 424-425.
66. H.F.A. Vasen, P. Watson, J.P. Mecklin, et al., New criteria for hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC (ICG-HNPCC), Gastroenterology 116 (1999) 1453-1456. (Pubitemid 29258894)
67. A. Umar, C.R. Boland, J.P. Terdiman, et al., Revised Bethesda Guidelines for hereditary polyposis colorectal cancer (Lynch syndrome) and microsatellite instability, J Natl Cancer Inst 96 (2004) 261-268. (Pubitemid 38256271)
68. A.R. Mensenkamp, I.P. Vogelaar, W.A.G. van Zelst-Stams, et al., Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors, Gastroenterology 146 (2014) 643-646.
69. N.M. Lindor, K. Rabe, G.M. Petersen, et al., Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X, JAMA 293 (2005) 1979-1985. (Pubitemid 40570891)
70. Y. Mueller-Koch, H. Vogelsang, R. Koop, et al., Hereditary nonpolyposis colorectal cancer: Clinical and molecular evidence for a new entity of hereditary colorectal cancer, Gut 54 (2005) 1733-1740. (Pubitemid 41697672)
71. X. Lior, E. Pons, R.M. Xicola, et al., Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway, Clin Cancer Res 11 (2005) 7304-7310. (Pubitemid 41507688)
72. L. Valle, J. Perea, P. Carbonell, et al., Clinicopathologic and pedigree differences in Amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status, J Clin Oncol 25 (2007) 781-786. (Pubitemid 350002877)
73. H.T. Lynch, P.M. Lynch, J. Pester, et al., The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome, Arch Intern Med 141 (1981) 607-611. (Pubitemid 11150094)
74. M.M. Entius, J.J. Keller, P. Drillenburg, et al., Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome, Clin Cancer Res 6 (2000) 1784-1789. (Pubitemid 30305072)
75. S.R. Hamilton, B. Liu, R.E. Parsons, et al., The molecular basis of Turcot's syndrome, N Engl J Med 332 (1995) 839-847.
76. C.E. Bronner, S.M. Baker, P.T. Morrison, et al., Mutations in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary nonpolyposis colon cancer, Nature 368 (1994) 258-261.
77. N.C. Nicolaides, N. Papadopoulos, B. Liu, et al., Mutations of two PMS homologues in hereditary nonpolyposis colon cancer, Nature 371 (1994) 75-80. (Pubitemid 24277467)
78. Y. Akiyama, H. Sato, T. Yamada, et al., Germ-line mutations of hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred, Cancer Res 57 (1997) 3920-3923. (Pubitemid 27427676)
79. M. Miyaki, M. Konishi, K. Tanaka, et al., Germline mutation of the hMSH6 gene as the cause of hereditary nonpolyposis colorectal cancer, Nat Genet 17 (1997) 271-272.
80. M.E. Kovacs, J. Papp, Z. Szentirmay, et al., Deletions removing the last exon of TA CSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome, Hum Mutat 30 (2009) 197-203.
81. H.T. Lynch, D.L. Riegert-Johnson, C. Snyder, et al., Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion, Am J Gastroenterol 106 (2011) 1829-1836.
82. M.J. Kempers, R.P. Kuiper, C.W. Ockeloen, et al., Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study, Lancet Oncol 12 (2011) 49-55.
83. A.K. Rustgi, The genetics of hereditary colon cancer, Genes Dev 21 (2007) 2525-2538. (Pubitemid 47607664)
84. C.P. Vaughn, J. Robles, J.J. Swensen, et al., Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes, Hum Mutat 31 (2010) 588-593.
85. E. Borràs, M. Pineda, J. Cadiñanos, et al., Refining the role of pms2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants, J Med Genet 50 (2013) 552-563.
86. M.P. Hitchins, R.L. Ward, Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary nonpolyposis colorectal cancer, J Med Genet 46 (2009) 793-802.
87. L.A. Aaltonen, P. Peltomaki, F.S. Leach, et al., Clues to the pathogenesis of familial colorectal cancer, Science 260 (1993) 812-816. (Pubitemid 23167611)
88. C.R. Boland, S.N. Thibodeau, S.R. Hamilton, et al., A National Cancer Institute Workshop of microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Res 58 (1998) 5248-5257. (Pubitemid 28521189)
89. Y. Wu, M.J. Berends, R.G. Mensink, et al., Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations, Am J Hum Genet 65 (1999) 1291-1298. (Pubitemid 30460379)
90. A.C. Haugen, A. Goel, K. Yamada, et al., Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer, Cancer Res 68 (2008) 8465-8472.
91. S.Y. Lee, H. Chung, B. Devaraj, et al., Microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasias, Gastroenterology 139 (2010) 1519-1525.
92. T. Hienonen, P. Laiho, R. Salovaara, et al., Little evidence for involvement of MLH3 in colorectal cancer predisposition, Int J Cancer 106 (2003) 292-296. (Pubitemid 36835186)
93. H.X. Liu, X.L. Zhou, T. Liu, et al., The role of hMLH3 in familial colorectal cancer, Cancer Res 63 (2003) 1894-1899. (Pubitemid 36460855)
94. N.M. Lindor, L.J. Burgart, O. Leontovich, et al., Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors, J Clin Oncol 20 (2002) 1043-1048. (Pubitemid 34141849)
95. J.M. Cunningham, C.Y. Kim, E.R. Christensen, et al., The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal cancers, Am J Hum Genet 68 (2001) 795-801.
96. G. Deng, I. Bell, S. Crawley, et al., BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer, Clin Cancer Res 10 (2004) 191-195. (Pubitemid 38114179)
97. E. Domingo, R.C. Niessen, C. Oliveria, et al., BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes, Oncogene 24 (2005) 3995-3998. (Pubitemid 40896411)
98. H. Nakagawa, T. Nagasake, H.M. Culling, et al., Efficient molecular screening of Lynch syndrome by specific 3 ′ promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability, Oncol Rep 21 (2009) 1577-1583.
99. J. Balmaña, F. Balaguer, S. Castellví-Bel, et al., Gastrointestinal Oncology Group of the Spanish Gastroenterological Association, comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients, J Med Genet 45 (2008) 557-563.
100. R.C. Green, P.S. Parfrey, M.O. Woods, et al., Prediction of Lynch syndrome in consecutive patients with colorectal cancer, J Natl Cancer Inst 101 (2009) 331-340.
101. F. Kastrinos, J.I. Allen, D.H. Stockwell, et al., Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy, Am J Gastroenterol 104 (2009) 1508-1518.
102. J.G. Monzon, C. Cremin, L. Armstrong, et al., Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer, Int J Cancer 126 (2010) 930-939.
103. C.R. Boland, M. Shike, Report from the Jerusalem Workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer, Gastroenterology 138 (2010) 2197-2201.
104. R.A. Barnetson, A. Tenesa, S.M. Farrington, et al., Identification and survival of carriers of mutations in DNA mismatch-repairs genes in colon cancer, N Engl J Med 354 (2006) 2751-2763. (Pubitemid 43974193)
105. F. Kastrinos, E.W. Steyerberg, R. Mercado, et al., The PREM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history, Gastroenterology (2011) 14073-14081.
106. T.A. Dinh, B.I. Rosner, J.C. Atwood, et al., Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population, Cancer Prev Res 4 (2010) 9-22.
107. G.E. Palomaki, M.R. McClain, S. Melillo, et al., EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome, Genet Med (2009) 1142-1165.
108. F. Kastrinos, E.W. Steyerberg, J. Balmaña, et al., Comparison of the clinical prediction model PREM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer, Gut 62 (2013) 272-279.
109. C. Julié, C. Trésallet, A. Brouquet, et al., Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening, Am J Gastroenterol 103 (2008) 2825-2835.
110. M.G. van Lier, C.H. Leenen, A. Wagner, et al., Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome, J Pathol 226 (2012) 764-774.
111. L. Pérez-Carbonell, C. Ruiz-Ponte, C. Guarinos, et al., Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer, Gut 61 (2012) 865-872.
112. L. Moreira, F. Balaguer, N. Lindor, et al., Identification of Lynch syndrome among patients with colorectal cancer, JAMA 308 (2012) 1555-1565.
113. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality for Lynch syndrome in relatives, Genet Med 11 (2009) 35-41.
114. U. Ladabaum, G. Wang, J. Terdiman, et al., Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis, Ann Intern Med 155 (2011) 69-79.
115. G.E. Palomaki, M.R. McClain, S. Melillo, et al., EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality for Lynch syndrome, Genet Med 11 (2009) 42-65.
116. M. Mvundura, S.D. Grosse, H. Hampel, et al., The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer, Genet Med 12 (2010) 93-104.
117. B. Heald, T. Plesec, X. Liu, et al., Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center, J Clin Oncol 31 (2013) 1336-1340.
118. E.M. Stoffel, A. Chitenden, Genetic testing for hereditary colorectal cancer: challenges in identifying, counseling, and managing high-risk patients, Gastroenterology 139 (2010) 1436-1441.
119. American Gastroenterological Association Medical Position Statement: hereditary colorectal cancer and genetic testing, Gastroenterology 121 (2001) 195-197.
120. F.M. Giardiello, J.D. Brensinger, G.M. Petersen, AGA technical review on hereditary colorectal cancer and genetic testing, Gastroenterology 121 (2001) 198-213. (Pubitemid 32591530)
121. Genetic testing for colon cancer: joint statement of the American College of Medical Genetics and American Society of Human Genetics. Joint Test and Technology Transfer Committee Working Group, Genet Med 2 (2000) 362-366.
122. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. Version 2.2012. http://www.nccn.org/ professionals/physician-gls/PDF/colorectal-screening.pdf. Accessed November 1, 2013.
123. M.E. Robson, C.D. Storm, J. Weitzel, et al., American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility, J Clin Oncol 28 (2010) 893-901.
124. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, J Clin Oncol 14 (1996) 1730-1740.
125. N.A. Holtzman, Promoting safe and effective genetic testing in the United States: work of the task force on genetic testing, Clin Chem 45 (1999) 732-738. (Pubitemid 29220348)
126. National Advisory Council for Human Genome Research, Statement on use of DNA testing for presymptomatic identification of cancer risk, J Am Med Assoc 271 (1994) 785.
127. American College of Surgeons. Commission on Cancer; standard 2.3: risk assessment and genetic counseling. Available at: http://www.facs.org/cancer/ cocsource/2012/february.html#. Accessed November 1, 2013.
128. J.D. Trimbath, F.M. Giardiello, Genetic testing and counseling for hereditary colorectal cancer, Aliment Pharmacol Ther 16 (2002) 1843-1857. (Pubitemid 35253000)
129. H.J. Järvinen, J.P. Mecklin, P. Sistonen, Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer, Gastroenterology 108 (1995) 1405-1411.
130. H.J. Järvinen, M. Aarnio, H. Mustonen, et al., Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer, Gastroenterology 118 (2000) 829-834. (Pubitemid 30243745)
131. H.J. Järvinen, L. Renkonen-Sinisalo, K. Aktán-Collán, et al., Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members, J Clin Oncol 27 (2009) 4793-4797.
132. I. Dove-Edwin, P. Sasieni, J. Adams, et al., Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, followup study, BMJ 331 (2005) 1047.
133. H.F. Vasen, M. Abdirahman, R. Brohet, et al., One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome, Gastroenterology 138 (2010) 2300-2306.
134. C. Engel, N. Rahner, K. Schulmann, et al., Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer, Clin Gastroenterol Hepatol 8 (2010) 174-182.
135. S. Stuckless, J.S. Green, M. Morgenstern, et al., Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation, Clin Genet 82 (2012) 439-445.
136. S. Grover, S. Sygal, Risk assessment, genetic testing and management of Lynch syndrome, J NCCN 8 (2010) 98-105.
137. N.M. Lindor, G.M. Petersen, D.W. Hadley, et al., Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review, JAMA (2006) 1507-1517. (Pubitemid 44465515)
138. H.F.A. Vasen, I. Blanco, K. Aktan-Collan, et al., Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts, Gut 62 (2013) 812-823.
139. I. Dove-Edwin, D. Boks, S. Goff, et al., The outcome of endometrial carcinoma surveillance by ultrasound in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma, Cancer 94 (2002) 1708-1712. (Pubitemid 34241108)
140. F.E. Rijcken, M.J. Mourits, J.H. Kleibeuker, et al., Gynecologic screening in hereditary nonpolyposis colorectal cancer, Gynecol Oncol 91 (2003) 74-80. (Pubitemid 37188596)
141. L. Renkonen-Sinisalo, R. Butzow, A. Leminen, et al., Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome, Int J Cancer 120 (2007) 821-824. (Pubitemid 46175402)
142. F. Lécuru, M.A. Le Frère Belda, A.S. Bats, et al., Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study, Int J Gynecol Cancer 18 (2008) 1326-1331.
143. L.H. Gerritzen, N. Hoogerbrugge, A.L. Oei, et al., Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome, Fam Cancer 8 (2009) 391-397.
144. S. Stuckless, J. Green, L. Dawson, et al., Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation, Clin Genet 83 (2013) 359-364.
145. D.G. Evans, K.N. Gaarenstroom, D. Stirling, et al., Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers, J Med Genet 46 (2009) 593-597.
146. K.M. Schmeler, H.T. Lynch, L.M. Chen, et al., Prophylactic surgery to reduce the risk of gynecological cancers in Lynch syndrome, N Engl J Med 354 (2006) 261-269. (Pubitemid 43113031)
147. K.Y. Yang, A.B. Caughey, S.E. Little, et al., A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) families, Fam Cancer 10 (2011) 535-543.
148. J.S. Kwon, C.C. Sun, S.K. Peterson, et al., Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome, Cancer 113 (2008) 326-335.
149. L. Renkonen-Sinisalo, P. Sipponen, M. Aarnio, et al., No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer, Scand J Gastroenterol 37 (2002) 574-577. (Pubitemid 34522923)
150. K. Schulmann, F.E. Brasch, E. Kunstmann, et al., HNPCC-associated small bowel cancer: clinical and molecular characteristics, Gastroenterology 128 (2005) 590-599. (Pubitemid 40585360)
151. J.C. Saurin, F. Pilleul, E.B. Soussan, et al., Small-bowel capsule endoscopy diagnoses early and advanced neoplasms in asymptomatic patients with Lynch syndrome, Endoscopy 42 (2010) 1057-1062.
152. T. Myrhøj, M.B. Andersen, I. Bernstein, Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer, Fam Cancer 7 (2008) 303-307.
153. E. Stoffel, B. Mukherjee, V.M. Raymond, et al., Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome, Gastroenterology 137 (2009) 1621-1627.
154. G.P. Thériault, C.G. Tremblay, B.G. Armstrong, Bladder cancer screening among primary aluminum production workers in Quebec, J Occup Med 32 (1990) 869-872. (Pubitemid 20301392)
155. Office of Disease Prevention and Health Promotion. Screening for bladder cancer. Available at: http://odphp.osophs.dhhs.gov/pubs/guidecps/PDF/CH17.PDF. Accessed November 1, 2013.
156. M.I. Canto, F. Harinck, R.H. Hruban, et al., International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer International Cancer of Pancreas Screening (CAPS) Consortium, Gut 62 (2013) 339-347.
157. P.J. Barrow, S. Ingham, C. O'Hara, et al., The spectrum of urological malignancy in Lynch syndrome, Fam Cancer 12 (2013) 57-63.
158. J.F. Haanstra, W.H. de Vos Tot Nederveen Cappel, J.P. Gopie, et al., Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy, Dis Colon Rectum 55 (2012) 653-659.
159. W.H. de Vos tot Nederveen Cappel, E. Buskens, P. van Duijvendijk, et al., Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect, Gut 52 (2003) 1752-1755. (Pubitemid 37510398)
160. M.F. Kalady, J. Lipman, E. McGannon, et al., Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer, Ann Surg 255 (2012) 1121-1125.
161. J. Burn, D.T. Bishop, J.P. Mecklin, et al., Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome, N Engl J Med 359 (2008) 2567-2578.
162. J.C. Mathers, M. Movahedi, F. Macrae, et al., Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomized controlled trial, Lancet Oncol 13 (2012) 1242-1249.
163. J. Burn, A.M. Gerdes, F. Macrae, et al., Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomized controlled trial, Lancet 378 (2011) 2081-2087.
164. P.M. Rothwell, F.G. Fowkes, J.F. Belch, et al., Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials, Lancet 377 (2011) 31-41.